Skip to content
Screener

EPS (Diluted) at other companies

TEC
Bio-TechneTECH
$0.32+129%
Bruker logo
BrukerBRKR
-$0.41-920%
Illumina logo
IlluminaILMN
$1.35-9.4%
Agilent Technologies logo
Agilent TechnologiesA
$1.20+60.0%
Quanterix Corporation logo
Quanterix CorporationQTRX
-$0.37+30.2%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
-$19.55-954%

Other financials

Income statement

See full
Revenue$151.0M-12.6%
Gross profit$112.5M-10.1%
Operating income-$19.6M-165%
Net income-$17.9M-152%

Balance sheet

See full
Cash & equivalents$502.5M+26.4%
Total debt$78.8M-9.2%
Total equity$825.5M+6.8%
Total assets$1.0B+5.1%

Cash flow

See full
Operating cash flow$17.0M-4.1%
CapEx$1.6M+0.6%
Free cash flow$15.4M-4.6%

Valuation

See full
Market cap$6.03B+287%
Enterprise value$5.6B+349%
P/S9.8×+7.4×

Profitability

See full
Gross margin70%+0.5pp
Operating margin-14.3%-1.1pp
Net margin-12.2%-0.8pp
FCF margin19.7%+10.9pp

Returns & leverage

See full
Return on equity-9.4%-1.4pp
Debt / equity0.1×0.0×
Current ratio5.7×-0.1×

Where this comes from

Reported directly by 10x Genomics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: 10x Genomics, Inc.’s 10-Q, filed August 7, 2026.

Filed
Aug 6, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054491
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total other income9106,8715,10912,693
Income (loss) before provision for income taxes(18,645)36,997(31,492)3,491
Provision for (benefit from) income taxes(714)2,459(91)3,311
Net income (loss)$(17,931)$34,538$(31,401)$180
Net income (loss) per share, basic$(0.14)$0.28$(0.24)$0.00
Net income (loss) per share, diluted$(0.14)$0.28$(0.24)$0.00
Weighted-average shares used to compute net income (loss) per share, basic129,984,169123,755,409129,050,312123,183,924
Weighted-average shares used to compute net income (loss) per share, diluted129,984,169124,509,720129,050,312124,258,150

Item 1. Financial Statements (Unaudited)

FAQ

What is 10x Genomics, Inc.'s EPS (diluted)?
10x Genomics, Inc. (TXG) reported EPS (diluted) of -$0.14 in Q2 2026.
How has 10x Genomics, Inc.'s EPS (diluted) changed year-over-year?
10x Genomics, Inc.'s EPS (diluted) decreased by 150.0% year-over-year, from $0.28 to -$0.14.
What is the long-term trend for 10x Genomics, Inc.'s EPS (diluted)?
Over 4 years (2021 to 2025), 10x Genomics, Inc.'s EPS (diluted) has grown at a -9.9% compound annual growth rate (CAGR), from -$0.53 to -$0.35.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about 10x Genomics, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude